Thus, the LLPS model proposed by Hnisz et al. (2017) might be used for the prediction of potential enhancers aberrantly activated in cancers for downstream transcriptional regulation at promoters, and for therapies targeting specific driver genes such as MYB or MYC to block downstream gene expression and protein translation. The gene discussed is MYC; the disease is cancer.